DESCRIBE <http://purl.uniprot.org/citations/15784872>

Subject	Predicate	Object
http://purl.uniprot.org/citations/15784872	http://www.w3.org/1999/02/22-rdf-syntax-ns#type	http://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/15784872	http://www.w3.org/2000/01/rdf-schema#comment	" Context Early response to multiagent chemotherapy, including mercaptopurine, as measured by minimal residual disease is an important prognostic factor for children with acute lymphoblastic leukemia (ALL). Thiopurine methyltransferase (TPMT) is involved in the metabolism of mercaptopurine and subject to genetic polymorphism, with heterozygous individuals having intermediate and homozygous mutant individuals having very low TPMT activity. Objective To assess the association of TPMT genotype with minimal residual disease load before and after treatment with mercaptopurine in the early treatment course of childhood ALL. Design, setting, and patients TPMT genotyping of childhood ALL patients (n = 814) in Germany consecutively enrolled in the ALL-BFM (Berlin-Frankfurt-Münster) 2000 study from October 1999 to September 2002. Minimal residual disease was analyzed on treatment days 33 and 78 for risk-adapted treatment stratification. A 4-week cycle of mercaptopurine was administered between these 2 minimal residual disease measurements. Patients (n = 4) homozygous for a mutant TPMT allele, and consequently deficient in TPMT activity, were treated with reduced doses of mercaptopurine and, therefore, not included in the analyses. Main outcome measures Minimal residual disease load before (day 33) and after (day 78) mercaptopurine treatment. Loads smaller than 10(-4) were defined as negative. Results Patients (n = 55) heterozygous for allelic variants of TPMT conferring lower enzyme activity had a significantly lower rate of minimal residual disease positivity (9.1%) compared with patients (n = 755) with homozygous wild-type alleles (22.8%) on day 78 (P = .02). This translated into a 2.9-fold reduction in risk for patients with wild-type heterozygous alleles (relative risk, 0.34; 95% confidence interval, 0.13-0.86). Conclusions TPMT genotype has a substantial impact on minimal residual disease after administration of mercaptopurine in the early course of childhood ALL, most likely through modulation of mercaptopurine dose intensity. Our findings support a role for minimal residual disease analyses in the assessment of genotype-phenotype associations in multiagent chemotherapeutic trials."xsd:string
http://purl.uniprot.org/citations/15784872	http://purl.org/dc/terms/identifier	"doi:10.1001/jama.293.12.1485"xsd:string
http://purl.uniprot.org/citations/15784872	http://purl.uniprot.org/core/author	"Zimmermann M."xsd:string
http://purl.uniprot.org/citations/15784872	http://purl.uniprot.org/core/author	"Eichelbaum M."xsd:string
http://purl.uniprot.org/citations/15784872	http://purl.uniprot.org/core/author	"Schaeffeler E."xsd:string
http://purl.uniprot.org/citations/15784872	http://purl.uniprot.org/core/author	"Zanger U.M."xsd:string
http://purl.uniprot.org/citations/15784872	http://purl.uniprot.org/core/author	"Schwab M."xsd:string
http://purl.uniprot.org/citations/15784872	http://purl.uniprot.org/core/author	"Bartram C.R."xsd:string
http://purl.uniprot.org/citations/15784872	http://purl.uniprot.org/core/author	"Schrappe M."xsd:string
http://purl.uniprot.org/citations/15784872	http://purl.uniprot.org/core/author	"Stanulla M."xsd:string
http://purl.uniprot.org/citations/15784872	http://purl.uniprot.org/core/author	"Welte K."xsd:string
http://purl.uniprot.org/citations/15784872	http://purl.uniprot.org/core/author	"Flohr T."xsd:string
http://purl.uniprot.org/citations/15784872	http://purl.uniprot.org/core/author	"Ludwig W.D."xsd:string
http://purl.uniprot.org/citations/15784872	http://purl.uniprot.org/core/author	"Cario G."xsd:string
http://purl.uniprot.org/citations/15784872	http://purl.uniprot.org/core/author	"Schrauder A."xsd:string
http://purl.uniprot.org/citations/15784872	http://purl.uniprot.org/core/date	"2005"xsd:gYear
http://purl.uniprot.org/citations/15784872	http://purl.uniprot.org/core/name	"JAMA"xsd:string
http://purl.uniprot.org/citations/15784872	http://purl.uniprot.org/core/pages	"1485-1489"xsd:string
http://purl.uniprot.org/citations/15784872	http://purl.uniprot.org/core/title	"Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia."xsd:string
http://purl.uniprot.org/citations/15784872	http://purl.uniprot.org/core/volume	"293"xsd:string
http://purl.uniprot.org/citations/15784872	http://www.w3.org/2004/02/skos/core#exactMatch	http://purl.uniprot.org/pubmed/15784872
http://purl.uniprot.org/citations/15784872	http://xmlns.com/foaf/0.1/primaryTopicOf	https://pubmed.ncbi.nlm.nih.gov/15784872
http://purl.uniprot.org/uniprot/#_P51580-mappedCitation-15784872	http://www.w3.org/1999/02/22-rdf-syntax-ns#object	http://purl.uniprot.org/citations/15784872
http://purl.uniprot.org/uniprot/#_Q9BS45-mappedCitation-15784872	http://www.w3.org/1999/02/22-rdf-syntax-ns#object	http://purl.uniprot.org/citations/15784872